Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -24% Improvement Relative Risk c19hcq.org Malundo et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 1,215 patients in Philippines (Mar - Sep 2021) Higher mortality with HCQ (not stat. sig., p=0.32) Malundo et al., IJID Regions, doi:10.1016/j.ijregi.2022.07.009 Favors HCQ Favors control
Predictors of Mortality among inpatients with COVID-19 Infection in a Tertiary Referral Center in the Philippines
Malundo et al., IJID Regions, doi:10.1016/j.ijregi.2022.07.009
Malundo et al., Predictors of Mortality among inpatients with COVID-19 Infection in a Tertiary Referral Center in the.., IJID Regions, doi:10.1016/j.ijregi.2022.07.009
Jul 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 1,215 hospitalized patients in the Phillipines, showing no significant difference in outcomes with remdesivir or HCQ use in unadjusted results subject to confounding by indication. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 24.4% higher, RR 1.24, p = 0.32, treatment 20 of 90 (22.2%), control 201 of 1,125 (17.9%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Malundo et al., 14 Jul 2022, retrospective, Philippines, peer-reviewed, 16 authors, study period 12 March, 2021 - 9 September, 2021.
Contact: agmalundo@up.edu.ph, annaflormalundo@gmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Journal Pre-proof Predictors of Mortality among inpatients with COVID-19 Infection in a Tertiary Referral Center in the Philippines Anna Flor G. Malundo , Cybele Lara R. Abad , Maria Sonia S. Salamat , Joanne Carmela M. Sandejas , Jonnel B. Poblete , Jose Eladio G. Planta , Shayne Julieane L. Morales , Ron Rafael W. Gabunada , Agnes Lorrainne M. Evasan , Johanna Patricia A. Cañal , Julian A. Santos , Jeffrey T. Manto , Maria Elizabeth P. Mercado , Raniv D. Rojo , Eric David B. Ornos , Marissa M. Alejandria PII: DOI: Reference: S2772-7076(22)00093-5 https://doi.org/10.1016/j.ijregi.2022.07.009 IJREGI 139 To appear in: IJID Regions Received date: Revised date: Accepted date: 25 February 2022 8 July 2022 11 July 2022 Please cite this article as: Anna Flor G. Malundo , Cybele Lara R. Abad , Maria Sonia S. Salamat , Joanne Carmela M. Sandejas , Jonnel B. Poblete , Jose Eladio G. Planta , Shayne Julieane L. Morales , Ron Rafael W. Gabunada , Agnes Lorrainne M. Evasan , Johanna Patricia A. Cañal , Julian A. Santos , Jeffrey T. Manto , Maria Elizabeth P. Mercado , Raniv D. Rojo , Eric David B. Ornos , Marissa M. Alejandria , Predictors of Mortality among inpatients with COVID-19 Infection in a Tertiary Referral Center in the Philippines, IJID Regions (2022), doi: https://doi.org/10.1016/j.ijregi.2022.07.009 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) Highlights  Our mortality data is comparable to early reports with the wild-type SARS-CoV-2.  Clinical and laboratory monitoring is critical on the 2nd to 3rd week of illness.  Common and inexpensive laboratory tests may aid in the monitoring of patients.  Clinical pathway can be adapted to local data, especially in resource-poor setting. 1 Predictors of Mortality among inpatients with COVID-19 Infection in a Tertiary Referral Center in the Philippines Anna Flor G. Malundoa, Cybele Lara R. Abadb, Maria Sonia S. Salamatb, Joanne Carmela M. Sandejasb, Jonnel B. Pobletec, Jose Eladio G. Plantab, Shayne Julieane L. Moralesb, Ron Rafael W. Gabunadab, Agnes Lorrainne M. Evasanb, Johanna Patricia A. Cañald, Julian A. Santosd, Jeffrey T. Mantod, Maria Elizabeth P. Mercadoe, Raniv D. Rojof, Eric David B. Ornosf, and Marissa M. Alejandriab a. Corresponding author: Address: Division of Infectious Diseases, University of the Philippines – Philippine General Hospital, Taft Avenue, Ermita, Manila, National Capital Region, Philippines Tel No: +63-02-8525-1062 ;+63-961-339-1325 Email: agmalundo@up.edu.ph or annaflormalundo@gmail.com b. Division of Infectious Diseases, University of the Philippines - Philippine General Hospital, Manila, Philippines c. Department of Medicine, University of the Philippines - Philippine General Hospital, Manila,..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit